Sign In
Buy VKTX
$38.86
-2.28 (-5.54%)
At Close: Jul 10, 2026
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
06:46pm, Friday, 10'th Jul 2026
Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting a -5.54% change compared to its last close.
Viking Therapeutics: Still Cheap, But Watch Double Top
11:50am, Friday, 10'th Jul 2026
Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, sugg
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength
05:34pm, Thursday, 09'th Jul 2026
Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or decisive breakout above major resistance will likely determine the next trend.
Is This Biotech Stock a Buy After Its Massive Rally?
03:00pm, Thursday, 09'th Jul 2026
Viking Therapeutics (VKTX +2.28%) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries serio
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
11:01am, Thursday, 09'th Jul 2026
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
3 High Growth GLP-1 Biotech Winners to Buy in July
08:00am, Thursday, 09'th Jul 2026
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
06:51pm, Wednesday, 08'th Jul 2026
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.
Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today
01:20pm, Tuesday, 07'th Jul 2026
A deepening sell-off in chip and memory stocks dragged all four major U.S. equity indexes lower by midday Tuesday.
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
10:36am, Tuesday, 07'th Jul 2026
CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market wi
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:35am, Monday, 06'th Jul 2026
CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
07:15am, Monday, 06'th Jul 2026
The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
01:05am, Sunday, 05'th Jul 2026
Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of pharma juggernauts.
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
05:10am, Saturday, 04'th Jul 2026
Viking Therapeutics is studying its weight loss drug candidate in late-stage trials. If all goes smoothly, the biotech could enter a market nearing $100 billion in the next few years.
Here's Why Viking Therapeutics Stock Surged Higher in June
09:25am, Friday, 03'rd Jul 2026
Viking's VK2735 has advantages over other weight-loss drugs, and investors anticipate positive results from Phase 3 trials in the coming years. The development of VK2735 as a dual formulation therapy
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:51pm, Wednesday, 01'st Jul 2026
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.
